Ixekizumab provides superior efficacy compared with ustekinumab over 52 weeks of treatment: Results from IXORA-S, a phase 3 study

Autor: Paul, C, Griffiths, CEM, van de Kerkhof, PCM, Puig, L, Dutronc, Y, Henneges, C, Dossenbach, M, Hollister, K, Reich, K

Publikováno v: JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname

Background: Biologics targeting interleukin 17A (IL-17A) allow for rapid clearance of psoriatic plaques, with a clinically favorable safety profile. Objectives: To compare the safety and efficacy of ixekizumab, an IL-17A antagonist, with the safety a

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=RECOLECTA___::4d079d804cdc29c21e9563ae0e22affe
https://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=3145

A 24‐week multicentre, randomized, open‐label, parallel‐group study comparing the efficacy and safety of ixekizumab vs. fumaric acid esters and methotrexate in patients with moderate‐to‐severe plaque psoriasis naive to systemic treatment

Autor: Reich, K., Augustin, M., Thaçi, D., Pinter, A., Leutz, A., Henneges, C., Schneider, E., Schacht, A., Dossenbach, M., Mrowietz, U.

Publikováno v: British Journal of Dermatology; Apr2020, Vol. 182 Issue 4, p869-879, 11p

Reply from Authors re: Arthur L. Burnett. Erection Rehabilitation After Radical Prostatectomy: Definite Purpose, Indefinite Strategy. Eur Urol 2014; 65: 597-8 Although Erection Rehabilitation After Prostatectomy Remains Indefinite, the Most Effective Treatment, the Earliest Recovery, and the Preservation of Erectile Function Remain a Definite Goal

Autor: Brock G, Buttner H, Henneges C, Mulhall J., MONTORSI , FRANCESCO

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od_____10495::9b2db1cbf8abb2b8a158090bfe415329

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

EFFECTS OF THE ONCE-DAILY CO-ADMINISTRATION OF TADALAFIL WITH FINASTERIDE FOR 6 MONTHS IN MEN WITH LOWER URINARY TRACT SYMPTOMS AND PROSTATIC ENLARGEMENT SECONDARY TO BENIGN PROSTATIC HYPERPLASIA: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL

Autor: Glina, S., Roehrborn, C. G., Ahmet Esen, Kapadia, K., Henneges, C., Buettner, H., Sorsaburu, S., Viktrup, L.

Publikováno v: Web of Science

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::589fab638b6c644edac38071fde61473
https://avesis.deu.edu.tr/publication/details/0638ca7d-9f4a-4aa1-974a-fceb6d7efccf/oai